Johnson & Johnson (J&J) will not enforce patents on its HIV drug Prezista (darunavir) for sale in poor countries as long as generic manufacturers make high-quality versions of the drug, Reuters reports. The drug is used when people develop resistance to older antiretroviral treatment. As such, the need for darunavir is expected to grow in poor countries as more people stop responding to their current regimens. The unilateral decision by J&J has disappointed some advocates who are calling for the company to share intellectual property rights in the Medicines Patent Pool, which streamlines generic production of HIV drugs.

To read the article, click here.